CLCF1 and neoplasm: Zhang et al. discovered that miR-30a-5p/CLCF1 could regulate sorafenib resistance in HCC, and treatment with cholesterol-modified agomiR-30a-5p significantly reduced tumor growth in mice harboring sorafenib-resistant HCC tumors [43].